ARS Pharmaceuticals Announces Neffy Epinephrine Nasal Spray Now Available By Prescription Across U.S. Following FDA Approval For Treatment Of Type I Allergic Reactions, Including Anaphylaxis
Portfolio Pulse from Benzinga Newsdesk
ARS Pharmaceuticals has announced that its Neffy Epinephrine Nasal Spray is now available by prescription in the U.S. This follows FDA approval for its use in treating Type I allergic reactions, including anaphylaxis.

September 23, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ARS Pharmaceuticals' Neffy Epinephrine Nasal Spray has received FDA approval and is now available by prescription in the U.S. for treating Type I allergic reactions, including anaphylaxis.
The FDA approval and availability of Neffy Epinephrine Nasal Spray is a significant milestone for ARS Pharmaceuticals, likely boosting investor confidence and potentially increasing sales and revenue. This positive development is expected to have a favorable impact on SPRY's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100